Poniard Pharmaceuticals Inc. (PARD)

Overview

Poniard Pharmaceuticals, Inc. is a distinguished biopharmaceutical entity dedicated to the advancement and commercialization of innovative cancer therapeutics. Originally established in 1984 as NeoRx Corporation, the company embarked on a new chapter of its journey by rebranding to Poniard Pharmaceuticals, Inc. in September 2006. With its headquarters rooted in Seattle, Washington, Poniard has positioned itself at the forefront of developing groundbreaking treatments aimed at offering new hope to patients battling various forms of cancer. The company’s efforts are propelled by a deep commitment to leveraging scientific advancements to ease the burden of cancer, striving to make a meaningful difference in the lives of patients and their families.

Products and Services

The core of Poniard Pharmaceuticals, Inc.'s innovation revolves around its lead platform product candidate, Picoplatin, a novel platinum-based therapy designed to combat a spectrum of cancer indications. Here is a detailed look at the key research areas and trial stages Picoplatin has undergone:

• Picoplatin for Small Cell Lung Cancer: At the pinnacle of its development pipeline is the pivotal Phase III SPEAR trial, targeting Picoplatin as a second-line treatment for patients suffering from small cell lung cancer. This indicates the company's commitment to addressing one of the most aggressive cancers, with the hope of providing a better quality of life for patients.
• First-Line Treatment of Metastatic Colorectal Cancer: Poniard has also embarked on Phase II clinical trials of Picoplatin as a first-line therapy for individuals diagnosed with metastatic colorectal cancer. This research effort underscores the company’s dedication to expanding Picoplatin’s therapeutic reach, potentially offering a new lifeline for patients facing this challenging diagnosis.
• Castration-Resistant Prostate Cancer: In its quest to diversify the applications of Picoplatin, Poniard is conducting Phase II trials aimed at evaluating the drug’s effectiveness in treating castration-resistant prostate cancer. This signifies an important step towards providing hope for patients contending with advanced stages of prostate cancer, striving for treatments that can better manage their condition.
• Oral Formulation of Picoplatin in Solid Tumors: Demonstrating Poniard’s innovative approach to cancer treatment, the company has initiated a Phase I study examining an oral formulation of Picoplatin. Aimed at solid tumors, this research venture represents a pivotal move towards enhancing patient convenience and adherence to treatment protocols, potentially transforming the landscape of cancer therapy.